MedTrace Logo

Impact of Patient Controlled Positive End-expiratory Pressure on Speech in Tracheostomized Ventilated Patients

NCT01479959 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2011-11-28

No results posted yet for this study

Summary

Adequate communication is a major part of the quality of life of tracheostomized ventilator dependent patients. Maintaining speech is therefore major goal in the management of these patients.

The use of a positive end-expiratory pressure (PEEP) during ventilation has allowed the improvement of speech. The best level for speech may vary from one patient to the other The purpose of this study is to determine individually the most efficient PEEP level in terms of speech while obtaining the most secure condition and the best possible respiratory tolerance. In order to improve the latter, the investigators will use a device which allows the patients to control the activation of PEEP so that they can use it only when needed (i.e. when they wish to speak). The investigators will compare the effect of different PEEP level to try to determine the best compromise to improve speech in tracheostomized ventilator-dependent patients.

Conditions

  • Chronic Respiratory Failure

Interventions

DEVICE

Eole 3 ventilator - Resmed

positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control

Sponsors & Collaborators

  • Adep Assistance

    collaborator OTHER

  • University of Versailles

    lead OTHER

Principal Investigators

  • Helene PRIGENT, MD · Hôpital Raymond Poincaré - APHP

  • Frederic LOFASO, MD-PhD · University of Versailles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01479959 on ClinicalTrials.gov